This invention provides a method of rapidly and reliably delivering sildenafil, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route so as to produce virtually instantaneous onset of beneficial effects in the treatment of erectile dysfunction. The present invention further provides pharmaceutical compositions comprising sildenafil, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without apomorphine.
The libido of adult human female patients is increased by the intrapulmonary delivery of testosterone. A formulation of testosterone is aerosolized and inhaled into a patient's lungs where particles of testosterone deposits on lung tissue and then enter the patient's circulatory system. The patient's testosterone level is enhanced well above baseline levels for a short period and subsides to baseline levels with normal metabolism thereby providing desired short term effects on enhanced libido without undesirable effects of long term enhanced testosterone levels. Additional formulations are provided including formulations for aerosolized delivery of sildenafil citrate which are delivered to male or female patients.
Disclosed are methods and compositions for treatment of male sexual dysfunction. A method of treating male sexual dysfunction includes administering a pharmaceutical composition effective to cause said male to sustain an erection. The composition is formulated based on diagnostic assessment and an individualized formulation test step. Also within the invention is a method of treating male sexual dysfunction in a population of subjects. The invention further provides kits for treatment of male erectile dysfunction.
A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.
The invention relates to a motor vehicle door hinge comprised of a first hinge part (2), a second hinge part (3), a shaft section (4), which joins a hinge eye (10) of the first hinge part (2) and a hinge eye (17) of the second hinge part (17) to one another in an articulated manner, and of a door arrester unit (25), which produces a holding force that is to be surmounted by tensioning a spring unit (32). Preferred holding angles of the door arrester unit (25) are stipulated by detent markings. The aim of the invention is to create a motor vehicle door hinge that can be economically produced and mounted. To this end, the hinge parts (2, 3) are provided in the form of U-shaped sheet metal shaped parts with hinge eyes (10, 11; 17, 18) that are placed in limbs (6, 7; 15, 16) of the hinge parts (2, 3), and the shaft section (4) is prevented from rotating with the one (26) of the cam disk (30) and detent disk (26) that is subjected to the action of the spring unit (32), whereas the other (30) of the cam disk (30) and detent disk (26) is joined in a non-rotatable manner to the hinge part (3) in which the shaft section can rotate.
A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.
